NuCana Reports Promising Clinical Data for NUC-3373

Nucana ( (NCNA) ) just unveiled an update.

On October 14, 2025, NuCana announced new data from the NuTide:303 clinical study, highlighting the efficacy and safety of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab. The study showed promising results, including significant tumor reduction in heavily pre-treated patients with advanced solid tumors. The findings, published in medRxiv and PLOS ONE, suggest that NUC-3373 enhances immune response and tumor cell death, supporting its potential as part of future cancer treatment regimens.

The most recent analyst rating on (NCNA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Nucana stock, see the NCNA Stock Forecast page.

Spark’s Take on NCNA Stock

According to Spark, TipRanks’ AI Analyst, NCNA is a Underperform.

Nucana’s overall score is primarily impacted by its financial instability and negative valuation metrics. The significant lack of revenue generation and operational losses are major concerns. Despite showing strong cash management and low leverage, the company’s technical indicators suggest a bearish trend, further weighing down the score. The poor valuation metrics, such as a negative P/E ratio, are offset by potential speculative interest due to the low stock price. The absence of notable earnings call insights or corporate events means these factors did not influence the score.

To see Spark’s full report on NCNA stock, click here.

More about Nucana

NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes by transforming chemotherapy agents into more effective and safer medicines using their ProTide technology. Their pipeline includes NUC-7738 and NUC-3373, which are being evaluated in clinical studies for various cancer treatments.

Average Trading Volume: 712,212

Technical Sentiment Signal: Sell

Current Market Cap: $10.17M

Learn more about NCNA stock on TipRanks’ Stock Analysis page.